Literature DB >> 8653684

Novel germline p16 mutation in familial malignant melanoma in southern Sweden.

A Borg1, U Johannsson, O Johannsson, S Häkansson, J Westerdahl, A Mäsbäck, H Olsson, C Ingvar.   

Abstract

The p16 (CDKN2/MTS1/INK4a) malignant melanoma susceptibility gene was analyzed in 10 melanoma kindreds from southern Sweden using single-stranded conformation polymorphism analysis of all three exons and flanking intron regions followed by sequence analysis. A novel germline mutation, constituting an in-frame 3-bp duplication at nucleotide 332 in exon 2, was identified in two families (Lund M2 and M9). The mutation results in an insertion of Arg at codon 105, which interrupts the last of the four ankyrin repeats of the p16 protein, motifs which have been demonstrated as important in binding and inhibiting the activity of cyclin D-dependent kinases 4 and 6 in cell cycle G1 phase regulation. All five tested individuals of Lund M2 and M9 affected by melanoma were mutation carriers, as were five melanoma-free individuals. Other malignancies observed in gene carriers or obligate carriers included cervical, breast, and pancreatic carcinomas and a non-Hodgkin's lymphoma. Analysis of microsatellite markers adjacent to the p16 gene at chromosomal region 9p21 revealed that both families share a common haplotype, in keeping with a common ancestor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8653684

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.

Authors:  P Ciotti; J P Struewing; M Mantelli; A Chompret; M F Avril; P L Santi; M A Tucker; G Bianchi-Scarrà; B Bressac-de Paillerets; A M Goldstein
Journal:  Am J Hum Genet       Date:  2000-06-22       Impact factor: 11.025

Review 2.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

3.  Rare germline variants in known melanoma susceptibility genes in familial melanoma.

Authors:  Alisa M Goldstein; Yanzi Xiao; Joshua Sampson; Bin Zhu; Melissa Rotunno; Hunter Bennett; Yixuan Wen; Kristine Jones; Aurelie Vogt; Laurie Burdette; Wen Luo; Bin Zhu; Meredith Yeager; Belynda Hicks; Jiali Han; Immaculata De Vivo; Stella Koutros; Gabriella Andreotti; Laura Beane-Freeman; Mark Purdue; Neal D Freedman; Stephen J Chanock; Margaret A Tucker; Xiaohong R Yang
Journal:  Hum Mol Genet       Date:  2017-12-15       Impact factor: 6.150

4.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.

Authors:  Alisa M Goldstein; May Chan; Mark Harland; Nicholas K Hayward; Florence Demenais; D Timothy Bishop; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarra; William Bruno; Donato Calista; Lisa A Cannon Albright; Valerie Chaudru; Agnes Chompret; Francisco Cuellar; David E Elder; Paola Ghiorzo; Elizabeth M Gillanders; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M MacKie; Veronica Magnusson; Graham J Mann; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

Review 5.  New developments in melanoma genetics.

Authors:  N Hayward
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

Review 6.  Familial melanoma: a complex disorder leading to controversy on DNA testing.

Authors:  Femke A de Snoo; Wilma Bergman; Nelleke A Gruis
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

7.  CDKN2A mutations and melanoma risk in the Icelandic population.

Authors:  A M Goldstein; S N Stacey; J H Olafsson; G F Jonsson; A Helgason; P Sulem; B Sigurgeirsson; K R Benediktsdottir; K Thorisdottir; R Ragnarsson; J Kjartansson; J Kostic; G Masson; K Kristjansson; J R Gulcher; A Kong; U Thorsteinsdottir; T Rafnar; M A Tucker; K Stefansson
Journal:  J Med Genet       Date:  2008-01-04       Impact factor: 6.318

8.  Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation.

Authors:  R Emig; A Magener; V Ehemann; A Meyer; F Stilgenbauer; M Volkmann; D Wallwiener; H P Sinn
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

9.  A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.

Authors:  A M Goldstein; L Liu; M G Shennan; D Hogg; M A Tucker; J P Struewing
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

10.  Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group.

Authors:  G Palmieri; A Cossu; P A Ascierto; G Botti; M Strazzullo; A Lissia; M Colombino; M Casula; C Floris; F Tanda; M Pirastu; G Castello
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.